Tags

Type your tag names separated by a space and hit enter

Flavonoid-based therapies in the early management of neurodegenerative diseases.
Adv Nutr. 2015 Jan; 6(1):64-72.AN

Abstract

During the past several years, there has been enormous progress in the understanding of the causative factors that initiate neuronal damage in various neurodegenerative diseases, including Alzheimer disease, Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington disease. Preventing neuronal damage and neuronal death will have a huge clinical benefit. However, despite major advances in causative factors that trigger these neurodegenerative diseases, to date there have been no therapies available that benefit patients who suffer from these diseases. Because most neurodegenerative diseases are late-onset and remain asymptomatic for most of the phases, the therapies initiated in advanced stages of the disease have limited value to patients. It may be possible to prevent or halt the disease progression to a great extent if therapies start at the initial stage of the disease. Such therapies may restore neuronal function by reducing or even eliminating the primary stressor. Flavonoids are key compounds for the development of a new generation of therapeutic agents that are clinically effective in treating neurodegenerative diseases. Regular consumption of flavonoids has been associated with a reduced risk of neurodegenerative diseases. In addition to their antioxidant properties, these polyphenolic compounds exhibit neuroprotective properties by their interaction with cellular signaling pathways followed by transcription and translation that mediate cell function under both normal and pathologic conditions. This review focuses on human intervention studies as well as animal studies on the role of various flavonoids in the prevention of neurodegenerative diseases.

Authors+Show Affiliations

School of Studies in Zoology and Biotechnology, Vikram University, Ujjain, India.School of Studies in Zoology and Biotechnology, Vikram University, Ujjain, India.School of Studies in Zoology and Biotechnology, Vikram University, Ujjain, India.School of Studies in Zoology and Biotechnology, Vikram University, Ujjain, India mdsparihar@gmail.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25593144

Citation

Solanki, Isha, et al. "Flavonoid-based Therapies in the Early Management of Neurodegenerative Diseases." Advances in Nutrition (Bethesda, Md.), vol. 6, no. 1, 2015, pp. 64-72.
Solanki I, Parihar P, Mansuri ML, et al. Flavonoid-based therapies in the early management of neurodegenerative diseases. Adv Nutr. 2015;6(1):64-72.
Solanki, I., Parihar, P., Mansuri, M. L., & Parihar, M. S. (2015). Flavonoid-based therapies in the early management of neurodegenerative diseases. Advances in Nutrition (Bethesda, Md.), 6(1), 64-72. https://doi.org/10.3945/an.114.007500
Solanki I, et al. Flavonoid-based Therapies in the Early Management of Neurodegenerative Diseases. Adv Nutr. 2015;6(1):64-72. PubMed PMID: 25593144.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Flavonoid-based therapies in the early management of neurodegenerative diseases. AU - Solanki,Isha, AU - Parihar,Priyanka, AU - Mansuri,Mohammad Lukman, AU - Parihar,Mordhwaj S, Y1 - 2015/01/15/ PY - 2015/1/17/entrez PY - 2015/1/17/pubmed PY - 2015/7/15/medline KW - antioxidant KW - bioactive compounds KW - cellular signaling KW - cognitive functions KW - flavonoids KW - mitochondria KW - neurodegenerative diseases KW - neuroprotection KW - oxidative stress SP - 64 EP - 72 JF - Advances in nutrition (Bethesda, Md.) JO - Adv Nutr VL - 6 IS - 1 N2 - During the past several years, there has been enormous progress in the understanding of the causative factors that initiate neuronal damage in various neurodegenerative diseases, including Alzheimer disease, Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington disease. Preventing neuronal damage and neuronal death will have a huge clinical benefit. However, despite major advances in causative factors that trigger these neurodegenerative diseases, to date there have been no therapies available that benefit patients who suffer from these diseases. Because most neurodegenerative diseases are late-onset and remain asymptomatic for most of the phases, the therapies initiated in advanced stages of the disease have limited value to patients. It may be possible to prevent or halt the disease progression to a great extent if therapies start at the initial stage of the disease. Such therapies may restore neuronal function by reducing or even eliminating the primary stressor. Flavonoids are key compounds for the development of a new generation of therapeutic agents that are clinically effective in treating neurodegenerative diseases. Regular consumption of flavonoids has been associated with a reduced risk of neurodegenerative diseases. In addition to their antioxidant properties, these polyphenolic compounds exhibit neuroprotective properties by their interaction with cellular signaling pathways followed by transcription and translation that mediate cell function under both normal and pathologic conditions. This review focuses on human intervention studies as well as animal studies on the role of various flavonoids in the prevention of neurodegenerative diseases. SN - 2156-5376 UR - https://www.unboundmedicine.com/medline/citation/25593144/Flavonoid_based_therapies_in_the_early_management_of_neurodegenerative_diseases_ L2 - https://academic.oup.com/advances/article-lookup/doi/10.3945/an.114.007500 DB - PRIME DP - Unbound Medicine ER -